What Are the Top Questions in ALL?

By Chadi Nabhan, MD, MBA, FACP, Elias Jabbour, MD - Last Updated: October 19, 2023

Elias Jabbour, MD, of the University of MD Anderson Cancer Center stops by The HemOnc Pulse for a live show at the Eleventh Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

In this episode, Dr. Jabbour, who is also an Associate Editor of Blood Cancers Today, the home of The HemOnc Pulse, discusses what he believes are the remaining questions in the treatment of acute lymphoblastic leukemia (ALL). He also discusses the possibility of moving away from chemotherapy for treating ALL and avoiding transplants by using chimeric antigen receptor (CAR)-T therapies.

“[I want to] not only decrease the chemotherapy, but walk away from transplant,” he said. “CAR-T cells can eventually replace autologous transplant.”

Dr. Jabbour acknowledged that in cases of relapse, there were various treatment options available. He stressed the importance of early intervention, stating that it was crucial to act as soon as possible to prevent multiple treatment failures. Some of these options include immunotherapies in the upfront setting and therapies targeting CD22 and CD20 in the second-line setting.

“There’s a lot of [therapies] coming down the road, but I think that it’s narrowing and narrowing … because my frontline therapy is getting so good to have less relapses, and hopefully I will have zero relapses down the road,” he said.


Editorial Board